Amgen Inc (AMGN) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Amgen Inc   (NASDAQ: AMGN)


Amgen Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Amgen Inc's ROI in the third quarter of 2026?
Amgen Inc achieved a return on average invested assets (ROI) of 13.92 % in its third quarter of 2026, this is above AMGN's average return on investment of 10.97%.
Amgen Inc s investments during the 12 months ending in the third quarter of 2026 are valued at $67 billion

ROI has improved compared to 13.36% in the second quarter of 2026, due to net income growth.

Within the Healthcare sector 35 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 659, from total ROI ranking in the second quarter of 2026 at 753.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 5.51 % 1.53 % -2.22 % -5.03 % -7 %
Y / Y Net Income Change TTM 34.06 % 32.09 % 50.38 % 123.05 % 147.53 %
Investment (TTM) in Millions 72,817 71,860 63,840 61,353 64,669
Return On Investment (TTM) 13.92 % 13.36 % 12.3 % 12.22 % 10.95 %
AMGN's Overall Ranking # 659 # 753 # 714 # 760 # 860
Seq. Investment Change TTM 3.11 % 3.22 % 0.48 % -1.34 % -0.77 %
Seq. Net Income Change TTM 7.41 % 12.09 % 1.15 % 10.08 % 5.83 %
Net Income (TTM) in Millions 9,391 8,743 7,800 7,711 7,005

AMGN Company Profile >> Back to AMGN Roi Comparisons >> See Annual AMGN Return On Investment



Return On Investment AMGN's Ranking
Within: No.
Industry # 8
Sector # 36
Overall # 659

Return On Investment Statistics
High Average Low
19.24 %
10.97 %
2.81 %
(Dec 31 2019)   (Dec 31 2017)







Financial Statements
Amgen Inc's III. Quarter Investments $ 72,817 Millions AMGN's Balance sheet
Amgen Inc's III. Quarter Income $ 3,864 Millions Quarterly AMGN's Income Statement
AMGN's Income by Division See AMGN's Income by Division


AMGN Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 61,353 64,775 74,082 46,772 48,981
Y / Y Investment Growth -5.28 % -12.56 % 58.39 % -4.51 % -4.51 %
Net Income in Millions 7,711 4,090 6,717 6,552 5,893
Y / Y Net Income Growth 88.53 % -39.11 % 2.52 % 11.18 % -18.87 %
Annual Return On Investment 12.57 % 6.31 % 9.07 % 14.01 % 12.03 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 12.57 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
AMGN's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for AMGN's Competitors
Subscribers only: Roi for Amgen Inc's Suppliers
Subscribers only: Return On Investment for AMGN's Customers

Other Ratios
AMGN's Roa AMGN's Inventory Turnover Ratio AMGN's Growth Rates AMGN's Dividend Statistics
AMGN's Profitability Ratios AMGN's Asset Turnover Ratio AMGN's Dividend Growth
AMGN's Roe AMGN's Valuation Ratios AMGN's Financial Strength Ratios AMGN's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Standard Biotools Inc   23.91 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %
Amgen Inc   13.64 %
Carlisle Companies Incorporated  13.64 %
Bristol myers Squibb Company  13.59 %
3m Company  13.24 %
Beone Medicines Ltd   13.17 %
Regeneron Pharmaceuticals Inc   13.00 %

Date modified: 2026-11-10T11:46:15+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.